A novel approach to deliver anticancer drugs to key cell types in tumors using a PDGF receptor-binding cyclic peptide...

Area of Science:

• Oncology
• Drug Delivery Systems
• Cancer Biology

Background:

• Tumor stromal cells play a crucial role in tumor progression.
• Targeting stromal cells alongside tumor cells may improve cancer treatment effectiveness.
• Platelet-Derived Growth Factor Receptor-beta (PDGFR-beta) is highly expressed on tumor stromal cells.

Purpose of the Study:

• To develop a targeted drug delivery system for PDGFR-beta-expressing tumor stromal cells.
• To enhance the therapeutic efficacy of anticancer drugs by co-delivering them to tumor and stromal cells.
• To evaluate the safety and efficacy of the novel drug conjugate in preclinical cancer models.

Main Methods:

• Albumin was modified with a PDGFR-beta-recognizing peptide (pPB-HSA) to create a targeted carrier.
• Doxorubicin was conjugated to pPB-HSA via an acid-sensitive hydrazone linkage (Dox-HSA-pPB).
• In vitro and in vivo studies were conducted using cancer cell lines and tumor models expressing PDGFR-beta.

Main Results:

• The Dox-HSA-pPB conjugate demonstrated specific binding and uptake by PDGFR-beta-expressing cells in vitro and in vivo.
• Treatment with Dox-HSA-pPB significantly inhibited tumor growth in a mouse model compared to free doxorubicin.
• The conjugate did not cause body weight loss, indicating reduced systemic toxicity compared to free doxorubicin.

Conclusions:

• Targeting PDGFR-beta on tumor stromal cells is a viable strategy for improving anticancer drug delivery.
• The developed Dox-HSA-pPB conjugate shows enhanced therapeutic efficacy and reduced toxicity.
• This novel approach offers a promising avenue for more effective cancer therapy by targeting key tumor microenvironment components.